Neuromyelitis optica

Researchers at Huashan Hospital are studying a practical management model for Chinese patients with neuromyelitis optica spectrum disorder (NMOSD) who receive satralizumab. The study follows about 100 patients aged 12 and older who test positive for AQP4 antibodies and have had r…

This study tests a drug called ravulizumab in about 19 Chinese adults with a rare autoimmune disease called NMOSD. The goal is to see if it can reduce the number of disease attacks (relapses) and slow disability. Participants must have had at least one attack in the past year and…

This early study tests a new treatment called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune disorders like multiple sclerosis and neuromyelitis optica. The treatment uses a patient's own immune cells that are modified in a lab to target and destr…

This study looks at whether giving satralizumab early during an attack of neuromyelitis optica spectrum disorder (NMOSD) can improve recovery and reduce long-term disability. Researchers will follow 50 adults with NMOSD who receive satralizumab as part of their routine care, trac…

This study tests a drug called satralizumab in children aged 2 to 11 who have a rare autoimmune disease called NMOSD. The main goal is to see how the drug moves through the body and if it can safely reduce relapses. Only 8 children will take part, and the results will help doctor…

This study tests whether injecting a person's own bone marrow stem cells into or near the eye can help treat various retinal and optic nerve diseases, including age-related macular degeneration, retinitis pigmentosa, and glaucoma. Participants receive stem cell injections via dif…

This study tests a new treatment called Modified Zipper Therapy for people with a rare disease called NMOSD. It combines standard treatments with a drug called eculizumab to help patients recover better from sudden attacks. About 198 adults will take part to see if this approach …

This early-phase trial is testing a new cell therapy called QH103 for people with severe autoimmune diseases like multiple sclerosis and myasthenia gravis that haven't responded to standard treatments. The therapy uses specially engineered immune cells to target and attack the fa…

This study tests an injection called B001 in 132 people with a severe nerve disease called NMOSD. The goal is to see if it can prevent sudden attacks that cause vision loss, paralysis, or other serious symptoms. Participants will receive either B001 or a placebo, and researchers …

This early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…

This early-phase trial tests a new drug called B001 in 45 people with a rare autoimmune disease called NMOSD. The study aims to check if B001 is safe, how the body processes it, and whether it might help control the disease. Participants must have had at least one relapse in the …

This study is testing whether adding eculizumab to standard steroid therapy helps people having an acute attack of neuromyelitis optica spectrum disorder (NMOSD). Researchers will follow 200 patients in China, comparing those who get eculizumab plus steroids to those who get ster…

This early-stage study tests a new cell therapy called CNCT19 in 18 adults with relapsed or treatment-resistant autoimmune neurological diseases like neuromyelitis optica. The goal is to see if it is safe and can help control the disease by targeting certain immune cells. Partici…

This early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates i…

This pilot study tests the drug ofatumumab in 5 people with a rare autoimmune disease called NMOSD. Participants receive injections over 48 weeks. The main goal is to see if the drug reduces the number of relapses compared to before treatment. It is an early, small study focused …

This early-stage trial tests a new treatment called NouvSoma001 for people with neuromyelitis optica spectrum disorders (NMOSD), a rare disease that causes inflammation in the eyes and spinal cord. The treatment uses tiny particles from stem cells, given via a spinal injection, t…

This early-stage study tests a new treatment using specially engineered immune cells (CAR T-cells) that target two proteins, CD19 and BCMA, to calm overactive immune attacks in people with severe autoimmune diseases like multiple sclerosis, myasthenia gravis, and neuromyelitis op…

This study tests a drug called inebilizumab in 15 children aged 2 to 17 with neuromyelitis optica spectrum disorder (NMOSD), a rare condition where the immune system attacks the optic nerves and spinal cord. The drug aims to reduce relapses by targeting certain immune cells. Rese…

This pilot study tests efgartigimod alfa (Vyvgart Hytrulo) against placebo in 20 adults having their first episode of moderate to severe optic neuritis, an inflammation of the optic nerve that can cause vision loss. Participants get two injections over a week, plus standard stero…

This registry study is tracking 200 people with a rare autoimmune disease called neuromyelitis optica spectrum disorder (NMOSD) who are positive for the AQP4 antibody. Researchers are evaluating how well monoclonal antibody therapies work in real-world settings, focusing on preve…

This trial tests whether individualized transcranial electrical stimulation (tES), a non-invasive brain stimulation technique, combined with cognitive training can improve thinking skills in people with central nervous system inflammatory demyelinating diseases like multiple scle…

This early-phase study tests a 4-week training program that uses mixed reality to guide precise movements, like stacking virtual objects. The goal is to see if this can improve walking speed, balance, and thinking in people with multiple sclerosis. Thirty adults with MS will part…

This study tests whether a device that sends mild electrical currents to the brain (hi-tACS) can improve sleep in people with neuroimmune diseases like multiple sclerosis who also have insomnia. Eighty participants will receive 20 sessions of the stimulation or a sham treatment. …

This study tests a non-invasive brain stimulation device (tTIS) to see if it can safely reduce neuropathic pain in people with neuromyelitis optica spectrum disorder (NMOSD). Twelve participants will receive the stimulation and report their pain levels. The goal is to find a new,…

This study follows 60 women with neuromyelitis optica spectrum disorder (NMOSD) who received UPLIZNA during pregnancy or within 6 months before conception. Researchers will collect data on pregnancy outcomes, including birth defects, preterm birth, and infant development over 10 …

This study is a pregnancy registry that gathers information from women with chronic neurological conditions like multiple sclerosis, NMOSD, and myasthenia gravis who are planning pregnancy, currently pregnant, or within one year postpartum. Participants can contribute blood, brea…

This study aims to discover biological markers (biomarkers) that could help doctors diagnose and track neurological autoimmune diseases such as multiple sclerosis, myasthenia gravis, and Guillain-Barre syndrome. Researchers will analyze samples from 50,000 people, including patie…

This study is analyzing inflammatory markers in the blood and spinal fluid of 300 people who are being checked for multiple sclerosis (MS). The goal is to see if certain markers can help doctors tell MS apart from other autoimmune diseases that affect the brain and spinal cord. R…

This study is a long-term registry for adults with AQP4+ neuromyelitis optica spectrum disorder (NMOSD) who are already taking Alexion C5 inhibitor drugs like eculizumab or ravulizumab. It will collect information on relapses, safety, and quality of life over many years to unders…

This study follows 100 women with neuroimmune diseases (like multiple sclerosis or myasthenia gravis) through pregnancy and up to five years after. Researchers will track disease activity, pregnancy complications, and baby health to learn how these conditions affect fertility and…

This observational study follows 170 people with multiple sclerosis, neuromyelitis optica, and similar conditions, plus healthy volunteers, for up to 6 years. Researchers use MRI scans, blood tests, and spinal fluid analysis to monitor brain lesions and understand how the disease…

The CLUE study is a research project that follows 1,000 people with neuroinflammatory diseases like multiple sclerosis and neuromyelitis optica. Participants undergo detailed MRI and PET scans at the start and after one year to see how their brain, spinal cord, and optic nerves c…

This study looks at whether a 10-minute video about palliative care can help people with multiple sclerosis (MS) understand their options and make decisions that match their values. Half of the 50 participants will watch the video, and the other half will read a standard informat…

This study follows 75 pregnant women who have taken Ultomiris (ravulizumab) for conditions like PNH or aHUS. Researchers will track pregnancy outcomes and baby health up to one year after birth. The goal is to gather safety information, not to test a new treatment.

This registry follows 1,500 women with multiple sclerosis (MS) or related conditions through pregnancy and after childbirth. Researchers will track relapses, use of disease-modifying drugs, and outcomes for both mothers and children. The goal is to better understand how MS and it…

This study gathers health data from 7,000 people with multiple sclerosis (MS) and related conditions. The goal is to use this information to train artificial intelligence (AI) tools that can help doctors diagnose MS earlier and predict how the disease will progress. No new treatm…

This study uses powerful MRI scanners to look at the brains and spinal cords of 700 people, including healthy volunteers and those with conditions like multiple sclerosis, Alzheimer's, and Parkinson's. The goal is to understand why some brains stay healthy while others decline. R…